|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Growth Opportunities in the EU Accession States: Healthcare Reform, Market Dynamics and Key Players
Business Insights, May 2006, Pages: 199
The expansion of the EU has created exciting opportunities for pharmaceutical companies to expand into new territories and take advantage of these high growth emerging markets; this report analyzes eight of the accession countries including the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia and Slovenia (The A8).
“Pharmaceutical Growth Opportunities in the EU Accession States” is a new report which provides in-depth insights into the competitive dynamics of the EU accession states. It identifies the key drivers and resistors of growth to enable you to understand the most important factors behind success in each country market. Use this latest report to determine key product opportunities, identify potential alliance partners and plan a successful and sustainable long term growth strategy to secure your leading position in the next five years.
Some key findings of the report...
Over the 2000-04 period, the A8 pharmaceutical market outperformed the EU5 with a CAGR of 17.6% as compared to the EU5 CAGR of 15.4%. The high growth of the A8 market over this pre-accession period can be partially attributed to the success of the mature branded generics market in the region, which continues to be a major focus of market development.
High growth has been seen across the A8 region in the 5 major therapy areas, in comparison to a more stable growth in the EU5. The A8 governments can restrict the level of prescription drug spending through pricing reimbursement regulations, which vary among the states.
The cardiovascular therapy area is the most significant therapeutic area in the A8 region with sales of $2,166m in 2004, with anti-hypertensives recording the highest sales. Drivers in the A8 cardiovascular market include generic competition in calcium channel blockers and angiotensin receptor blocker classes. However, sales growth was slow in 2004, at 8.6%, mainly due to a lack of innovation in the area and the impact on price through increased generic competition.
Key questions answered in this report
- What are the factors impacting the structure of each country market pre and post-accession?
- What are the current trends within the major therapy areas of cardiovascular, cancer, respiratory, anti-infectives and CNS disorders across the 8 largest EU Accession markets?
- How significant is the threat on branded products from the growth of the generics market?
- What are the key strategies for major pharmaceutical companies entering and operating within the EU Accession states?
- Which companies are best positioned to succeed in the A8 pharmaceutical market over the period 2005-11?
- What is the forecast market size and growth rates over the period 2005-2011 across the major indications?
Top five reasons to order your copy today
- Gain a quick and comprehensive understanding of the competitive dynamics of the A8 pharmaceutical market, external factors driving market growth, leading therapeutic areas and licensing trends.
- Identify how social, economic, political, and regulatory changes have and will continue to affect the A8 pharmaceutical market and analyze the competitive responses from pharmaceutical companies.
- Analyze the key issues facing pharmaceutical marketers and understand how they will drive future sales of branded and generic products.
- Understand which therapy areas have the greatest potential to catalyze franchise growth and how the pharmaceutical industry can effectively exploit these opportunities.
- Determine the most attractive growth opportunities for branded products and which indications are forecast to come under the strongest pressure from generic competitors.
|
|
|
|
